Skip to main navigation Skip to search Skip to main content

IDeate-Prostate01: A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeateProstate01)

Project: Research

Project Details

StatusActive
Effective start/end date07/21/25 → 04/30/30

Funding

  • Merck Sharp and Dohme Limited Liability Corporation: $103,296.62